HRP20130986T1 - Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze - Google Patents
Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze Download PDFInfo
- Publication number
- HRP20130986T1 HRP20130986T1 HRP20130986AT HRP20130986T HRP20130986T1 HR P20130986 T1 HRP20130986 T1 HR P20130986T1 HR P20130986A T HRP20130986A T HR P20130986AT HR P20130986 T HRP20130986 T HR P20130986T HR P20130986 T1 HRP20130986 T1 HR P20130986T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydrogen
- compound according
- compound
- methyl
- fluoro
- Prior art date
Links
- HOTKFUUWGWLIKF-UHFFFAOYSA-N NC=1C=CNN=1.N1SC2=NN=NC2=N1 Chemical compound NC=1C=CNN=1.N1SC2=NN=NC2=N1 HOTKFUUWGWLIKF-UHFFFAOYSA-N 0.000 title 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 title 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- -1 chloro, cyclopropyl Chemical group 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Spoj koji ima formulu:
[image]
ili njegova farmaceutski prihvatljiva sol, u kojem
R1 je C1-3 alifatik;
R2 je vodik, fluoro ili metil;
R3 je vodik, fluoro ili metil;
svaki R4 je, nezavisno, vodik ili fluoro; i
R5 je vodik, kloro, ciklopropil ili C1-4 alifatik, izborno supstituiran sa 1-3 atoma fluora.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je R2 jednak metil i R3 je vodik.
3. Spoj prema patentnom zahtjevu 2, naznačen time što je R1 jednak metil i R5 je vodik.
4. Spoj prema patentnom zahtjevu 1, naznačen time što je R2 jednak vodik i R3 je metil.
5. Spoj prema patentnom zahtjevu 4, naznačen time što je R1 jednak metil i R5 je vodik.
6. Spoj prema patentnom zahtjevu 1, naznačen time što je svaki od R2 i R3 jednak fluoro.
7. Spoj prema patentnom zahtjevu 6, naznačen time što je R1 jednak metil i R5 je vodik.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je R4 jednak vodik.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je R4 jednak fluoro.
10. Spoj prema patentnom zahtjevu 1, naznačen time što ima slijedeću strukturu:
[image]
[image]
[image]
11. Spoj prema patentnom zahtjevu 1, naznačen time što ima slijedeću strukturu:
[image]
12. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, adjuvant ili prenositelj.
13. Kompozicija prema patentnom zahtjevu 12, naznačena time što dodatno sadrži kemoterapeutsko ili anti-proliferativno sredstvo, anti-inflamatorno sredstvo, sredstvo za liječenje ateroskleroze ili sredstvo za liječenje plućne fibroze.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili farmaceutska kompozicija prema patentnom zahtjevu 12 ili 13 koja sadrži navedeni spoj, za uporabu u liječenju ili smanjenju težine proliferativnog poremećaja kod pacijenta.
15. Spoj ili kompozicija, za uporabu prema patentnom zahtjevu 14, pri čemu je navedeni poremećaj metastazirajući kancer.
16. Spoj ili kompozicija, za uporabu prema patentnom zahtjevu 14, pri čemu je navedeni poremećaj glioblastom; karcinom želudca; ili kancer izabran od kancera debelog crijeva, dojke, prostate, mozga, jetre, pankreasa ili pluća.
17. Spoj ili kompozicija, za uporabu prema patentnom zahtjevu 14, pri čemu je navedeni poremećaj hepatostanični karcinom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18178609P | 2009-05-28 | 2009-05-28 | |
| PCT/US2010/036312 WO2010138665A1 (en) | 2009-05-28 | 2010-05-27 | Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130986T1 true HRP20130986T1 (hr) | 2013-11-22 |
Family
ID=42346870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130986AT HRP20130986T1 (hr) | 2009-05-28 | 2013-10-17 | Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP2435443B1 (hr) |
| JP (1) | JP5686796B2 (hr) |
| KR (1) | KR20120030110A (hr) |
| CN (1) | CN102459283B (hr) |
| AR (1) | AR076617A1 (hr) |
| AU (1) | AU2010254055B2 (hr) |
| BR (1) | BRPI1012037A2 (hr) |
| CA (1) | CA2762190A1 (hr) |
| CL (1) | CL2011002946A1 (hr) |
| DK (1) | DK2435443T3 (hr) |
| ES (1) | ES2433090T3 (hr) |
| HK (1) | HK1169105A1 (hr) |
| HR (1) | HRP20130986T1 (hr) |
| IL (1) | IL216581A (hr) |
| MX (1) | MX2011012521A (hr) |
| NZ (1) | NZ596616A (hr) |
| PL (1) | PL2435443T3 (hr) |
| PT (1) | PT2435443E (hr) |
| RS (1) | RS53011B (hr) |
| RU (1) | RU2552993C2 (hr) |
| SG (1) | SG176574A1 (hr) |
| SI (1) | SI2435443T1 (hr) |
| TW (1) | TWI491614B (hr) |
| UA (1) | UA106082C2 (hr) |
| WO (1) | WO2010138665A1 (hr) |
| ZA (1) | ZA201108655B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102448968A (zh) * | 2009-05-28 | 2012-05-09 | 沃泰克斯药物股份有限公司 | C-met蛋白激酶的取代的吡唑抑制剂 |
| US8263777B2 (en) | 2010-05-27 | 2012-09-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase |
| TR201113223A2 (tr) * | 2011-12-29 | 2012-06-21 | Koçak Farma İlaç Ve Ki̇mya Sanayi̇ A. Ş. | Pemetrekset disodyum hazırlanmasına yönelik tek basamaklı işlem. |
| KR101373912B1 (ko) | 2012-03-26 | 2014-03-13 | 중앙대학교 산학협력단 | Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법 |
| CN108853108A (zh) * | 2015-12-31 | 2018-11-23 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| CN109897054B (zh) * | 2017-12-08 | 2021-12-10 | 中国药科大学 | 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| ZA200501536B (en) * | 2002-08-14 | 2006-10-25 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
| US7122548B2 (en) * | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| KR101156845B1 (ko) * | 2007-05-21 | 2012-06-18 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 헤테로시클릭 키나제 조절제 |
| EP2365977B1 (en) * | 2008-11-19 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | A triazolothiadiazole derivative as inhibitor of c-met protein kinase |
| CN102448968A (zh) * | 2009-05-28 | 2012-05-09 | 沃泰克斯药物股份有限公司 | C-met蛋白激酶的取代的吡唑抑制剂 |
-
2010
- 2010-05-27 EP EP10721904.0A patent/EP2435443B1/en active Active
- 2010-05-27 DK DK10721904.0T patent/DK2435443T3/da active
- 2010-05-27 KR KR1020117031139A patent/KR20120030110A/ko not_active Application Discontinuation
- 2010-05-27 PL PL10721904T patent/PL2435443T3/pl unknown
- 2010-05-27 WO PCT/US2010/036312 patent/WO2010138665A1/en active Application Filing
- 2010-05-27 SG SG2011085578A patent/SG176574A1/en unknown
- 2010-05-27 ES ES10721904T patent/ES2433090T3/es active Active
- 2010-05-27 BR BRPI1012037A patent/BRPI1012037A2/pt not_active IP Right Cessation
- 2010-05-27 PT PT107219040T patent/PT2435443E/pt unknown
- 2010-05-27 RS RS20130471A patent/RS53011B/en unknown
- 2010-05-27 SI SI201030410T patent/SI2435443T1/sl unknown
- 2010-05-27 UA UAA201115482A patent/UA106082C2/uk unknown
- 2010-05-27 JP JP2012513241A patent/JP5686796B2/ja not_active Expired - Fee Related
- 2010-05-27 RU RU2011153613/04A patent/RU2552993C2/ru not_active IP Right Cessation
- 2010-05-27 NZ NZ596616A patent/NZ596616A/xx not_active IP Right Cessation
- 2010-05-27 MX MX2011012521A patent/MX2011012521A/es active IP Right Grant
- 2010-05-27 AU AU2010254055A patent/AU2010254055B2/en not_active Ceased
- 2010-05-27 CN CN201080028334.XA patent/CN102459283B/zh not_active Expired - Fee Related
- 2010-05-27 CA CA2762190A patent/CA2762190A1/en not_active Abandoned
- 2010-05-28 TW TW099117257A patent/TWI491614B/zh not_active IP Right Cessation
- 2010-05-28 AR ARP100101868A patent/AR076617A1/es unknown
-
2011
- 2011-11-22 CL CL2011002946A patent/CL2011002946A1/es unknown
- 2011-11-24 IL IL216581A patent/IL216581A/en active IP Right Grant
- 2011-11-24 ZA ZA2011/08655A patent/ZA201108655B/en unknown
-
2012
- 2012-10-03 HK HK12109702.6A patent/HK1169105A1/xx not_active IP Right Cessation
-
2013
- 2013-10-17 HR HRP20130986AT patent/HRP20130986T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010138665A1 (en) | 2010-12-02 |
| CA2762190A1 (en) | 2010-12-02 |
| HK1169105A1 (en) | 2013-01-18 |
| EP2435443A1 (en) | 2012-04-04 |
| IL216581A0 (en) | 2012-02-29 |
| PT2435443E (pt) | 2013-10-31 |
| TWI491614B (zh) | 2015-07-11 |
| RU2011153613A (ru) | 2013-07-10 |
| NZ596616A (en) | 2013-05-31 |
| DK2435443T3 (da) | 2013-10-28 |
| SG176574A1 (en) | 2012-01-30 |
| EP2435443B1 (en) | 2013-07-31 |
| SI2435443T1 (sl) | 2013-12-31 |
| UA106082C2 (uk) | 2014-07-25 |
| PL2435443T3 (pl) | 2014-01-31 |
| ZA201108655B (en) | 2013-01-30 |
| CL2011002946A1 (es) | 2012-07-27 |
| CN102459283A (zh) | 2012-05-16 |
| IL216581A (en) | 2014-02-27 |
| AU2010254055B2 (en) | 2016-01-14 |
| BRPI1012037A2 (pt) | 2016-05-17 |
| ES2433090T3 (es) | 2013-12-09 |
| MX2011012521A (es) | 2012-01-30 |
| RS53011B (en) | 2014-04-30 |
| JP5686796B2 (ja) | 2015-03-18 |
| KR20120030110A (ko) | 2012-03-27 |
| AR076617A1 (es) | 2011-06-22 |
| JP2012528186A (ja) | 2012-11-12 |
| TW201100436A (en) | 2011-01-01 |
| CN102459283B (zh) | 2014-11-12 |
| AU2010254055A1 (en) | 2011-12-15 |
| RU2552993C2 (ru) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130986T1 (hr) | Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
| HRP20171030T1 (hr) | Modulatori enzima koji modificiraju metil, njihove smjese i uporaba | |
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20171961T1 (hr) | Kemijski spojevi | |
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| HRP20131081T1 (hr) | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20180804T1 (hr) | Inhibitori dnk-pk | |
| JP2019537570A5 (hr) | ||
| RS53898B1 (en) | QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | |
| NZ626942A (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| JP2013523802A5 (hr) | ||
| RU2015107552A (ru) | Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения | |
| HRP20180538T1 (hr) | Inhibitori za erk i postupci njihove uporabe | |
| JP2015529235A5 (hr) | ||
| HRP20220840T1 (hr) | Inhibitori receptora faktora rasta fibroblasta | |
| RS53385B (en) | DERIVATIVES OF HINAZOLIN-4 (3H) -ONE USED AS PI3 KINASE INHIBITOR | |
| TN2013000401A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
| HRP20140705T1 (hr) | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina | |
| HRP20120785T1 (hr) | Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze | |
| CL2014000395A1 (es) | Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor. |